BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 23, 2024
See today's BioWorld
Home
» IPO now: Axovant flies from formation to $172.5M offering
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
IPO now: Axovant flies from formation to $172.5M offering
May 13, 2015
By
Michael Fitzhugh
No Comments
Axovant Sciences Ltd., a small Bermuda-based company formed in October to carry a phase-III-ready asset bought from Glaxosmithkline plc through approval in Alzheimer's disease (AD), has filed for an IPO of up to $172.5 million.
BioWorld
